Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Cancer Immunotherapy Drug Discovery Outsourcing Market Worth $1.7 Billion by 2025: Grand View Research, Inc.

This image opens in the lightbox

News provided by

Grand View Research, Inc

19 Feb, 2019, 10:35 GMT

Share this article

Share toX

Share this article

Share toX

SAN FRANCISCO, Feb. 19, 2019 /PRNewswire/ -- The global cancer immunotherapy drug discovery outsourcing market size is projected to reach USD 1.7Billion by 2025, according to a new report by Grand View Research, Inc., rising at a CAGR of 13.5% during the forecast period. Increasing prevalence of cancer and rising mortality associated with cancer, along with growing development in the field of cancer immunotherapy, are anticipated to stimulate the growth of the market.

Key suggestions from the report:

  • Monoclonal antibodies emerged as the largest segment in 2017 because of increasing regulatory approvals and higher efficacy
  • Target identification and validation accounted for the largest share in the global market owing to higher costs incurred and increased investments in new drug development
  • North America dominated the market with the largest share in 2017. Rising incidence of cancer and increasing demand for novel technologies are facilitating the dominance of the region during the forecast period
  • Some of the key players are Covance, Inc.; Explicyte; Aquila BioMedical; Horizon Discovery Group PLC; Crown Bioscience, Inc.; Promega Corporation; HD Biosciences Co., Ltd.; BPS Bioscience, Inc.; Genscript Biotech Corporation; DiscoverX Corporation; Celentyx Ltd.; ImmunXperts SA; Personalis, Inc.; STC Biologics; and Molecular Imaging, Inc. dominated the cancer immunotherapy drug discovery outsourcing market.

Read 95 page research report with TOC on "Cancer Immunotherapy Drug Discovery Outsourcing Market Analysis Report By Drug, By Service, By Cancer Type (Lung, Breast, Colorectal, Melanoma, Prostate, Pancreatic), And Segment Forecasts, 2018 - 2025" at:  https://www.grandviewresearch.com/industry-analysis/cancer-immunotherapy-drug-discovery-outsourcing-market

In order to maintain pace with increasing competition in the cancer therapeutics industry, pharmaceutical companies spend 2.5% more than other high tech industries in the in-house R&D. Hence, they are swiftly shifting towards outsourcing of drug discovery in order to achieve lower in-house R&D costs.

Additionally, favorable tax credit allows pharmaceutical companies to appropriately plan their global projects with a reputed CRO and therefore, receive benefits and reduce problems associated with taxation authorities or other bodies administering such incentive programs.

Several new molecules for cancer immunotherapy and new immunotherapeutic options, such as tumor infiltrating lymphocytes, check point inhibitors immunomodulators, and CAR-T cell therapy, have been introduced. Some are in the pipeline and are being tested for their ability to provide better cancer treatment

Grand View Research has segmented the global cancer immunotherapy drug discovery outsourcing market based on drug type, service type, cancer type, and region:

  • Cancer Immunotherapy Drug Discovery Outsourcing Drug Type Outlook (Revenue, USD Million, 2014 - 2025)
    • Monoclonal Antibodies
    • Immunomodulators
    • Oncolytic Viral Therapies and Cancer Vaccines
  • Cancer Immunotherapy Drug Discovery Outsourcing Service Type Outlook (Revenue, USD Million, 2014 - 2025)
    • Target Identification and Validation
    • Lead Screening and Characterization
    • Cell Based Assays
  • Cancer Immunotherapy Drug Discovery Outsourcing Cancer Type Outlook (Revenue, USD Million, 2014 - 2025)
    • Lung Cancer
    • Breast Cancer
    • Colorectal Cancer
    • Melanoma
    • Prostate Cancer
    • Head and Neck Cancer
    • Ovarian Cancer
    • Pancreatic Cancer
  • Cancer Immunotherapy Drug Discovery Outsourcing Regional Outlook (Revenue, USD Million, 2014 - 2025)
    • North America
      • U.S.
      • Canada
    • Europe
      • U.K.
      • Germany
    • Asia Pacific
      • India
      • China
    • Latin America
      • Brazil
      • Mexico
    • Middle East & Africa
      • South Africa

Find more research reports on Biotechnology Industry, by Grand View Research:

  • Cell Banking Outsourcing Market – The Global cell banking outsourcing market size was valued at USD 2.93 billion in 2014 and is expected to grow at an estimated CAGR of 16.4% from 2015 to 2022.
  • Genomics In Cancer Care Market - The global cancer genomics market size was valued at USD 9,216 million in 2014 and is expected to grow at CAGR of 17.3% over the forecast period.
  • Oncology based Molecular Diagnostics Market – The Global oncology based molecular diagnostics market size was valued at USD 1,136.5 million in 2014 and is expected to grow at a CAGR of 14.7% over the forecast period.

Gain access to Grand View Compass, our BI enabled intuitive market research database of 10,000+ reports

About Grand View Research

Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.

Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc.
Phone: +1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com
Web: https://www.grandviewresearch.com
Follow Us: LinkedIn | Twitter

Modal title

Also from this source

Point Of Care Diagnostics Market Size to be $68.5 Billion by 2030 at CAGR 5.8% - Grand View Research, Inc.

Point Of Care Diagnostics Market Size to be $68.5 Billion by 2030 at CAGR 5.8% - Grand View Research, Inc.

The global point of care diagnostics market size is expected to reach USD 68.5 billion by 2030, registering a CAGR of 5.8% from 2025 to 2030,...

Sports Betting Market Size to Hit $187.39 Billion by 2030 at CAGR 11.0% - Grand View Research, Inc.

Sports Betting Market Size to Hit $187.39 Billion by 2030 at CAGR 11.0% - Grand View Research, Inc.

The global sports betting market size is estimated to reach USD 187.39 billion by 2030, registering a CAGR of 11% from 2025 to 2030, according to a...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

Pharmaceuticals

Pharmaceuticals

Biotechnology

Biotechnology

News Releases in Similar Topics

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.